Maxim Group Analysts Give Vistagen Therapeutics (VTGN) a $6.00 Price Target
Other equities analysts have also issued research reports about the stock. Oppenheimer started coverage on shares of Vistagen Therapeutics in a research report on Thursday, May 24th. They set a buy rating and a $6.00 price target for the company. Zacks Investment Research raised shares of Vistagen Therapeutics from a hold rating to a buy rating and set a $1.50 price target for the company in a research report on Thursday, August 30th. Chardan Capital reaffirmed a buy rating and set a $22.00 price target on shares of Vistagen Therapeutics in a research report on Friday, June 29th. Finally, UBS Group started coverage on shares of Vistagen Therapeutics in a research report on Thursday, May 24th. They set an outperform rating and a $6.00 price target for the company. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus price target of $8.30.
Shares of VTGN stock opened at $1.36 on Thursday. Vistagen Therapeutics has a one year low of $0.69 and a one year high of $2.65.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Further Reading: What is intrinsic value?
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.